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Why do male fig wasps bite
each others’ heads off? What
male fig wasps do with their short
lives in the syconium varies
hugely between species. In some,
males peacefully stumble around,
ignoring each other and focusing
their efforts on finding females to
mate with. In others, males are
aggressive, and spend a large
proportion of their time fighting
each other. In some cases,
fighting involves huge mandibles
that are used to chop off rivals’
heads (Figure 3). What makes
some fig wasps so mean to each
other that they can even
decapitate their own brothers?
Males are most aggressive when
there are not many females for
them to mate: the males then fight
viciously to monopolise those
females — they do not have much
to lose. In species where lots of
females develop in each fruit, an
individual female is not worth
fighting over, and so a male is
better off just searching
peacefully for other females to
mate.
How many fig wasps are there?
We do not have a really good
estimate (a common problem with
insects), but can make an
informed guess. There are about
750 fig species: if each has its
own pollinator species, shared
with no other fig, that makes 750
pollinators, but up to half of fig
species have two or more
pollinators, so call it 1200.
Including a rough estimate for the
fig-parasitic wasps, from several
different taxonomic groups,
makes 8700 species, a number
that goes up if there are
(inevitably) cryptic parasite
species and down if some
parasites are less host-specific
than we think. Basically, there are
probably about as many fig wasp
species as bird species (~10,000).
Do we eat fig wasps? Figs taste
great, but do you get a mouthful
of dead wasps every time you eat
one? Not really, as long as you eat
the right figs. About half of all fig
species, including the edible fig,
are functionally dioecious
(individual trees produce either
seeds or pollen). This involves
having male trees with wasp and
pollen-producing syconia and
female trees with seed-producing
syconia. We only eat the seed-
producing figs, but where are the
wasps? A few foundresses enter
each seed fig and pollinate the
flowers, but they die frustrated as
they are unable to lay eggs
successfully in these female
flowers, which differ from the
wasp-friendly ones found in gall
syconia. In this case, the fig
seems to have solved the problem
of flower use by separating its
wasp and seed-rearing tasks on
different trees. And some
cultivated fig varieties produce
ripe syconia without the need for
pollination or wasps at all. This is
convenient, but a bit mundane in
comparison with the natural
history of figs and fig wasps!
Where can I find out more?
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Figure 3. A formidable Sycoscapter
fighting male with large jaws and spiked
legs. (Copyright James Cook.)Primer 
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Schizophrenia is a frightening
illness in which intrusive ‘voices’
(auditory hallucinations) torment
the sufferer with abusive or
derogatory comments, and ideas
weave together to form false
beliefs (delusions), which colonise
the mind. The sufferer may
become convinced he is under
surveillance or enmeshed in a
conspiracy of huge religious or
political importance. He may
believe that his thoughts are no
longer private or that they are
controlled by an external —
usually malevolent — will. The
experiences feel real; the new
version of reality and the
sufferer’s place in it resist
correction by reason.
Occasionally, patients act on their
delusions with disastrous results.
Most people recover from their
first schizophrenic episode within
a few weeks of receiving
antipsychotic drugs, but with
each succeeding episode the
hallucinations and delusions —
termed ‘positive symptoms’ —
become more resistant to
treatment, and negative
symptoms, such as loss of
motivation, poverty of thought,
and emotional blunting, gradually
accumulate. Negative symptoms
are often accompanied by
cognitive impairment, especially
executive (frontal lobe) and
memory (temporal lobe) deficits.
Dopamine as the ‘wind of
psychotic fire’
Arvid Carlsson, who won the
Nobel Prize for his work on
neurotransmitters, suggested four
decades ago that an excess in
brain dopamine levels underlies
schizophrenic symptoms.
However, it was only directly
demonstrated in 1996 that acutely
psychotic patients release
excessive striatal dopamine in
response to an amphetamine
challenge. Furthermore, the
degree of dopamine release
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severity of the positive symptoms
and with subsequent response to
dopamine blockers. But why
should an excess of striatal
dopamine make someone think
that their neighbours are out to
poison them or that the CIA have
planted a chip in their brain? In
2003, Shitij Kapur proposed an
attractive theory, which linked the
dopamine hypothesis to clinical
symptoms. He suggested that in a
normal individual, mesolimbic
dopamine provides an external
stimulus, or an internal thought,
with significance or salience, i.e.,
it converts its mental
representation from a neutral
piece of information into one that
‘grabs the attention’ of the
individual. Since acute psychosis
is associated with increased
release of dopamine, salience will
be given inappropriately to what
would otherwise have been
regarded as insignificant events
and perceptions.
Whilst Carlsson’s original theory
implied an overall
hyperdopaminergic state in the
brain, the modern view is that the
excess in mesolimbic dopamine is
indeed responsible for the
positive symptoms, whereas
negative symptoms and executive
deficits are the result of deficient
dopamine in the frontal cortex.
Some believe that the impaired
(and dopamine deficient)
prefrontal cortex fails to ‘brake’
the limbic system, and the
resultant increased mesolimbic
dopamine causes the increased
salience and overreaction to
stimuli, which ultimately leads to
paranoia and psychosis.
Neural development and function
Although the onset of florid
psychosis is usually early in adult
life, children destined to develop
schizophrenia often show subtle
developmental delays and deficits
in motor and cognitive function;
they tend to be solitary, and show
an excess of social anxiety. These
childhood delays and deficits
have been taken as indicating that
schizophrenia is in part a
neurodevelopmental disorder.
Support for this view has also
come from neuroimaging and
neuropathological studies.Figure 1. Brain activation during random sampling of auditory hallucinations. 
Transverse fMRI sections below (left and middle, -13 mm and -7 mm, respectively) and
above (right, +4 mm) the anterior commisure. Viewed from the ventral side, the right
side of the brain is shown on the left of each section. Subcortical and cortical areas of
the auditory pathway are engaged during auditory hallucinations: The left section shows
activation of the inferior colliculus. In the right section there is activation in the tempo-
ral cortex and in Broca’s area (BA). Reproduced with permission from Shergill et al.
Temporal
cortex
BAMRI studies have consistently
demonstrated that people with
schizophrenia have an increased
lateral ventricular volume, and
show a slight decrease in cortical
volume (2%) with greater
decrements (about 5%) in the
hippocampus, amygdala and
thalamus. Such brain
abnormalities are present at the
onset of the illness. Post-mortem
studies largely confirm the
volumetric findings, and show an
absence of cell loss or other
signs of neurodegeneration,
which has also supported the
developmental view. Some
studies have suggested
subsequent loss of cortical grey
matter but it is not clear whether
this loss is due to some intrinsic
process or to the effects of
antipsychotics.
Functional MRI (fMRI) has
begun to elucidate some of the
abnormal physiology underlying
schizophrenia. Auditory
hallucinations, for instance, are
associated with an activation of
Broca’s area in the prefrontal
cortex where ‘inner speech’ is
produced, as well as with certain
temporal and sub-cortical areas,
which normally process external
speech (Figure 1). It is as if the
auditory processing system does
not recognise the individual’s own
inner speech as self-generated,
and instead processes it as if it
were derived from outside.
Similarly, fMRI studies have
demonstrated that negative
symptoms and planning
difficulties are associated with an
inability to activate pre-frontal
areas efficiently in response to
cognitive challenge.Susceptibility genes
If one identical twin has
schizophrenia, the chance is
about 40% that the second twin
will also manifest the illness. The
risk is less than 10% if they are
non-identical, and falls off
rapidly in second and third
degree relatives of affected
individuals, suggesting that the
mode of transmission involves
multiple genes rather than a
single gene of large effect. Until
recently, the search for genes for
schizophrenia resembled that for
Weapons of Mass Destruction in
Iraq — many people believed
they were there but nobody
could find them. However, unlike
the former, susceptibility genes
for schizophrenia do exist
(Table 1).
In 2002, the deCODE genetics
group in Iceland identified 8p21-
22 as the likely location of a
suceptibility gene, and then fine-
mapped the region. An
association between
schizophrenia and a seven-
marker haplotype (an extended
series of polymorphisms) in
neuregulin 1 (NRG1) was found.
The findings were replicated with
affected individuals from
Scotland and Wales, as well as
from South Africa and China,
although in the latter studies the
risk haplotype differed from that
in the Icelandic sample. Despite
some negative studies, the weight
of evidence supports the
association between NRG1 and
schizophrenia. Furthermore,
heterozygous mice with 50%
NRG1 expression show a
phenotype with certain similarities
to schizophrenia; some of these
Current Biology Vol 15 No 24
R982can be reversed by the
antipsychotic clozapine.
Another susceptibility gene,
dysbindin (DTNBP1) was identified
on 6p22.3. As with neuregulin 1,
the at-risk haplotype varies
between populations and the
specific allelic variant (or variants)
conferring risk of schizophrenia
remains unknown. Some other
candidate genes are emerging
from clues provided by
chromosomal abnormalities found
in some people with
schizophrenia: These are too rare
to account for more than a small
fraction of the cases of
schizophrenia. For instance, up to
25% of sufferers from the velo-
cardio-facial-syndrome (DiGeorge
Syndrome), which results from a
deletion on 22q11, develop
psychosis. Genes in the deleted
region have, therefore, attracted
much interest; particularly,
Catechol-O-Methyltransferase
(COMT) and Proline
Dehydrogenase (PRODH) are
appealing candidates, as they are
components of the dopamine and
glutamate signalling systems,
respectively.
Investigation of a large Scottish
family in which a rare balanced
translocation of chromosomes 1
and 11 segregated with
psychiatric illness led to the
identification of a gene at the
breakpoint at 1q42, which was
unimaginatively termed Disrupted
in Schizophrenia 1 (DISC1). Other
groups have subsequently
reported positive linkage for
DISC1, which binds proteins like
NUDEL and microtubule
Table 1. Candidate schizophrenia genes.
Gene Function
Neuregulin1 Neuronal migration,
glutamate signalling 
Dysbindin Glutamate release
DISC1 Neuronal migration
RGS4 Synaptic signalling 
AKT1 Synaptic signalling 
COMT Dopamine catabolism
Proline Glutamate chemistry
dehydrogenase
GRM3 Glutamate signalling
DAOA/G72 Glutamate signallingassociated proteins, and thus may
be involved in neuronal migration,
neurite outgrowth or cytokinesis.
The list of candidates continues
to grow, and includes regulator of
G protein signalling (RGS4),
DAOA/G72, AKT1, and GRM3 (see
Table 1). However, these
candidates are not yet well
replicated.
Schizophrenia — a synaptic
disorder?
With the exception of DISC1, all
known susceptibility genes code
for synaptic proteins (Figure 2).
This is not surprising, as there is
reduced dendritic spine density in
the cortex and hippocampus of
schizophrenics and diminished
levels of synaptic markers, such
as synaptophysin and the
complexin proteins have been
observed consistently. 
The major fast
neurotransmitters in the CNS are
glutamate (excitatory) and GABA
(inhibitory). Glutamate has been
suspected to be involved in
schizophrenia because drugs like
phencyclidine (PCP) and
ketamine, which block NMDA
channels, can induce a psychosis
that mimics both positive and
negative symptoms. The products
of several susceptibility genes are
part of the glutamate system:
PRODH and DAOA/G72 code for
proteins involved in glutamate
signalling while the Neuregulin 1
receptor ErbB, forms a
functionally important complex
with glutamate NMDA receptors.
Finally, Dysbindin is involved in
the vesicular release of glutamate;
in the schizophrenic
hippocampus, Dysbindin immuno-
reactivity is decreased at
glutamate terminals and dysbindin
mRNA and protein are decreased
in schizophrenic prefrontal cortex.
As yet, no susceptibility genes
involved in GABA signalling have
emerged. However, the GABA-
ergic Chandelier neurons in the
dorsolateral prefrontal cortex of
schizophrenia patients exhibit
markedly reduced levels of
GAD67, a GABA synthesizing
enzyme, and GAT1, the GABA
membrane transporter;
concomitantly, GABAA receptors
are up-regulated on post-synaptic
glutamate neurons. However, it isimpossible to say whether these
changes are primary or constitute
downstream adaptations to other
neurochemical events.
Dopamine interacts directly with
both GABA and glutamatergic
neurotransmission, but, in
contrast to these, it is involved in
slow transmission and has a
modulatory function, especially in
regulating plasticity at glutamate
synapses. Thus, dopamine acting
at D1/D5 receptors is a
requirement for long-term
modification of glutamate
synapses in the hippocampus, the
prefrontal cortex and the ventral
striatum. Indeed, Eric Kandel and
colleagues have recently shown
that dopamine appears to be
necessary for the maintenance of
both long-term potentiation and
long-term depression at
glutamatergic synapses in the
pre-frontal cortex. Dopamine
signalling seems to be particularly
important in ‘stamping in’ memory
for salient events, so if it is
dysregulated in psychosis,
spurious excitatory connections
and aberrant networks could
develop over time, manifesting as
persistent delusional beliefs or
thought disorder.
Environmental factors 
Schizophrenia is not just a genetic
disorder as evidenced by the fact
that the risk of the identical co-
twin of an affected individual
developing the disorder is only
about 40%. In recent years,
environmental factors contributing
to risk have been identified.
Individuals exposed to a range
of obstetric hazards, such as pre-
maturity, low birth weight, and
hypoxia, are at increased risk of
developing schizophrenia, and
such patients are particularly
likely to show a decreased volume
of the hippocampus. Animal
studies have modelled such
insults. For example, lesioning the
ventral hippocampus in neonatal
rats decreases the density of
dendritic spines in the prefrontal
cortex and accumbens nuclei and
the animals show exaggerated
response to amphetamine after
reaching maturity.
A curious but consistent finding
is that individuals with
schizophrenia are 7–10% more
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spring. One possible explanation
is winter infection in mothers, and
a number of studies have reported
that foetuses exposed to prenatal
maternal infections, ranging from
influenza to rubella and
toxoplasmosis, are more likely to
grow up to develop schizophrenia.
Humans and animals repeatedly
exposed to amphetamine become
sensitised to the drug, and with
successive exposures, release
increased amounts of dopamine.
Of course, humans are usually
exposed to amphetamine in the
context of abuse, and this is well
known to induce schizophrenia-
like psychosis in a proportion of
heavy abusers. 
More surprisingly, seven
epidemiological studies have also
shown that sustained heavy
cannabis use increases the risk of
schizophrenia in later life two- to
fourfold; the earlier abuse begins,
the higher the risk. The
mechanism by which cannabis
confers risk is unknown though it
has been shown in rodents to
increase the release of dopamine
in the nucleus accumbens. A very
interesting recent finding is that
variation in the COMT gene,
mentioned earlier, modulates the
risk conferred by cannabis. COMT
metabolises dopamine in the
prefrontal cortex, and a valine at
position 158 of the protein
(Met158Val) doubles its enzymatic
activity. Teenagers homozygous
for the valine genotype show a
particularly high risk of
schizophrenia later in life if they
abuse cannabis.
Schizophrenia lies at the
interface between brain and the
social environment, so any
plausible aetiological model of
schizophrenia needs to
incorporate the evidence that
social factors modulate risk. It has
long been known that patients
commonly have their first
psychotic episode at times of
great stress, and those whose
relatives are hostile towards them
show the worst outcome. Now we
also know that being born or
brought up in a city increases risk,
as does migration from one
country to another. The most
striking example of the latter is the
consistent evidence that AfricansFigure 2. Schizophrenia — disorder at synapses.
Schematic diagram of putative mechanisms of susceptibility gene products (shown in
red) at glutamate and dopaminergic synapses in schizophrenia. Terminals of glutamate
(Glu) and dopamine (DA) neurons are shown synapsing at a dendritic spine. Neuregulin1
activates the ErbB receptor, leading to internal sequestration of NMDA receptors (not
shown). Dysbindin (Dys) is involved in pre-synaptic glutamate release, whilst D-amino
acid oxidase activator (DAOA) regulates the metabolism of serine, an essential co-
agonist of NMDA receptors. Catechol-O-methyltransferase (COMT) inactivates
dopamine in the pre-frontal cortex. (D1/D5: dopamine receptors; Gs: G protein; AC:
adenylate cyclase; PKA: protein kinase A; CREB: cAMP response element binding
protein; AMPA: AMPA glutamate receptor; NMDA: NMDA glutamate receptor).
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Dendritic
spineand African-Caribbeans living in
England show an incidence of
schizophrenia at least 6 times that
of the native white population.
Social isolation and lack of social
support may play a role, and
animal studies have shown that
the mesolimbic dopamine system
can be manipulated by social
signals.
Therapy
Reliable definitions of
schizophrenia — the DSMIV
classification of the American
Psychiatirc Organization and the
ICD-10 definition of the World
Health Organization — are now
widely used. Nevertheless, the
boundaries of schizophrenia are
not distinct and it blends on one
side into bipolar disorder (manic-
depression), and on the other into
schizotypal and paranoid
personality. It has also become
clear that a proportion of the
general adult population
experience brief or isolatedpsychotic phenomena without
coming into contact with
psychiatric services. Most
authorities now consider liability
to psychosis to be a continuous
trait in populations, like
hypertension, and that individuals
categorised as schizophrenic lie
at the extreme end of a
continuum. The healthy relatives
of schizophrenics often show
schizoid or schizotypal
characteristics, and their
performance on cognitive tests is
intermediate between that of
patients and normal subjects.
The discovery of
chlorpromazine in the early 1950s
enabled people with
schizophrenia to be treated as
outpatients for the first time, and
led ultimately to the closure of the
old asylums. Subsequently a
range of other antipsychotic drugs
were developed, all of which
share the ability to block
dopamine D2 receptors. For
almost half a century, these
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remained the basis of therapy.
Typical antipsychotics decrease
positive symptoms but often lead
to a loss of emotional
responsivity, which is not
surprising given the role of
dopamine in reward, as well as to
extrapyramidal side-effects
(stiffness, tremor and symptoms
resembling Parkinson’s disease).
Furthermore, they are not very
effective for the treatment of
negative symptoms or cognitive
impairment.
In the late 1980s, clozapine was
found to be more potent than
typical antipsychotics and also to
improve negative symptoms
without causing extra-pyramidal
side-effects. Unfortunately, it has
many other side-effects.
Therefore, a range of effective
‘atypical’ antipsychotics were
developed which do indeed have
less motor side-effects; the best
known of these are risperidone
and olanzapine. However, none of
the atypicals have the clinical
potency of clozapine.
Of course, successful treatment
doesn’t just involve giving
antipsychotic drugs. Because
schizophrenic patients show acute
sensitivity to stress, it is important
to find the right social niche in
which they can function best. In
recent years, cognitive behaviour
therapy has been introduced as an
adjunctive treatment. Initially, this
was addressed at the depression
and anxiety, which many patients
find more troubling than the
auditory hallucinations, but
recently encouraging results have
come from studies attempting to
persuade patients to re-evaluate
the evidence for their delusional
beliefs.
At present, the only attempt at
prevention is by treating those
‘prodromal’ individuals who are on
the brink of developing psychosis.
Currently much effort is going into
identifying those defined as
having the ‘at risk mental state’,
up to 40% of whom develop frank
psychosis within one or two years.
Whether or not to treat them is a
matter of heated debate. Some
believe that with a combination of
cognitive behaviour therapy and
low dose antipsychotics, we could
prevent a significant proportionfrom developing the illness.
Others point out that even if this
were true, it would be at the cost
of giving antipsychotic drugs to a
majority of individuals who would
probably never develop
psychosis.
Conclusions
The identification of susceptibility
genes and their apparent
convergence at the synapse is a
major development in
understanding the pathogenesis
of schizophrenia. Individually,
each gene (and environmental risk
factor) has a small effect size; for
example, the relative risk for those
carrying the respective risk
haplotypes of neuregulin1 and
dysbindin is less than two. It is
likely that to develop
schizophrenia an individual needs
to inherit a number of
susceptibility genes and to
encounter various adverse
environmental factors. This may
be explained by compensatory
changes or redundancy of
signalling pathways at the
synapse. If there are multiple
‘hits’, additional or compensatory
pathways may be compromised
and signalling impaired.
Work is now focussing on
investigating the effect of
combinations of risk factors. This
approach has the potential to
identify the key components
involved in schizophrenia.
Although the complexity of
synapses makes this task
difficult, the positive aspect is
that there are potentially many
more targets available for drug
development.
Ultimately, this will lead to a
better understanding of
pathogenesis, and open up the
possibility of prevention at a
public health level. Our present
attempts at intervention at the
prodromal stage are far too late
and are aimed at symptoms, not
their precursors. Hopefully, in the
future we will have ways of
identifying children or young
adults who show the
endophenotypes that underlie
schizophrenia, and have safe
ways of arresting the pathogenic
processes long before the
clinical symptoms manifest
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